Breaking Finance News

Immunomedics, Inc. (NASDAQ:IMMU) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.

Having a price of $2.63, Immunomedics, Inc. (NASDAQ:IMMU) traded -1.15% lower on the day. With the last stock price down -14.96% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. IMMU has recorded a 50-day average of $2.98 and a two hundred day average of $3.03. Trade Volume was up over the average, with 2,720,997 shares of IMMU changing hands over the typical 1,367,830

Zacks Investment Research has upgraded Immunomedics, Inc. (NASDAQ:IMMU) to Hold in a statement released on Friday October 07, 2016.

Recent Performance Chart

Immunomedics, Inc. (NASDAQ:IMMU)

Immunomedics, Inc. has with a one year low of $1.61 and a one year high of $5.44 and has a market capitalization of $0.

A total of 1 brokerage has issued a ratings update on Immunomedics, Inc.. Two brokerages rating the company a strong buy, zero brokerages rating the company a buy, zero brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $5.00.

General Company Details For Immunomedics, Inc. (NASDAQ:IMMU)

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.